A 0 1 0 1 O
participant 2 13 2 13 O
who 14 17 14 17 O
has 18 21 18 21 O
had 22 25 22 25 O
extensive 26 35 26 35 B-clinical_variable
colitis 36 43 36 43 I-clinical_variable
for 44 47 44 47 O
greater 48 55 48 55 O
than 56 60 56 60 O
or 61 63 61 63 O
equal 64 69 64 69 O
to 70 72 70 72 O
( 73 74 73 74 O
> 74 75 74 75 O
=) 75 77 75 77 O
8 78 79 78 79 B-lower_bound
years 80 85 80 85 I-lower_bound
, 85 86 85 86 O
or 87 89 87 89 O
disease 90 97 90 97 B-clinical_variable
limited 98 105 98 105 I-clinical_variable
to 106 108 106 108 I-clinical_variable
the 109 112 109 112 I-clinical_variable
left 113 117 113 117 I-clinical_variable
side 118 122 118 122 I-clinical_variable
of 123 125 123 125 I-clinical_variable
the 126 129 126 129 I-clinical_variable
colon 130 135 130 135 I-clinical_variable
for 136 139 136 139 O
> 140 141 140 141 O
= 141 142 141 142 O
12 143 145 143 145 B-lower_bound
years 146 151 146 151 I-lower_bound
, 151 152 151 152 O
must 153 157 153 157 O
either 158 164 158 164 O
have 165 169 165 169 O
had 170 173 170 173 O
a 174 175 174 175 O
colonoscopy 176 187 176 187 B-treatment
to 188 190 188 190 O
assess 191 197 191 197 O
for 198 201 198 201 O
the 202 205 202 205 O
presence 206 214 206 214 O
of 215 217 215 217 O
dysplasia 218 227 218 227 B-chronic_disease
within 228 234 228 234 O
1 235 236 235 236 B-upper_bound
year 237 241 237 241 I-upper_bound
before 242 248 242 248 O
the 249 252 249 252 O
first 253 258 253 258 O
administration 259 273 259 273 O
of 274 276 274 276 O
study 277 282 277 282 O
agent 283 288 283 288 O
or 289 291 289 291 O
a 292 293 292 293 O
colonoscopy 294 305 294 305 O
to 306 308 306 308 O
assess 309 315 309 315 O
for 316 319 316 319 O
the 320 323 320 323 O
presence 324 332 324 332 O
of 333 335 333 335 O
malignancy 336 346 336 346 B-cancer
at 347 349 347 349 O
the 350 353 350 353 O
screening 354 363 354 363 O
visit 364 369 364 369 O
, 369 370 369 370 O
with 371 375 371 375 O
no 376 378 376 378 O
evidence 379 387 379 387 O
of 388 390 388 390 O
malignancy 391 401 391 401 O

Adhere 0 6 402 408 O
to 7 9 409 411 O
the 10 13 412 415 O
following 14 23 416 425 O
requirements 24 36 426 438 O
for 37 40 439 442 O
concomitant 41 52 443 454 O
medication 53 63 455 465 O
for 64 67 466 469 O
the 68 71 470 473 O
treatment 72 81 474 483 O
of 82 84 484 486 O
Crohn 85 90 487 492 B-chronic_disease
's 90 92 492 494 I-chronic_disease
disease 93 100 495 502 I-chronic_disease
, 100 101 502 503 O
which 102 107 504 509 O
are 108 111 510 513 O
permitted 112 121 514 523 O
provided 122 130 524 532 O
that 131 135 533 537 O
doses 136 141 538 543 O
meeting 142 149 544 551 O
these 150 155 552 557 O
requirements 156 168 558 570 O
are 169 172 571 574 O
stable 173 179 575 581 O
, 179 180 581 582 O
or 181 183 583 585 O
have 184 188 586 590 O
been 189 193 591 595 O
discontinued 194 206 596 608 O
, 206 207 608 609 O
for 208 211 610 613 O
at 212 214 614 616 O
least 215 220 617 622 O
3 221 222 623 624 B-lower_bound
weeks 223 228 625 630 I-lower_bound
before 229 235 631 637 O
baseline 236 244 638 646 O
( 245 246 647 648 O
Week 246 250 648 652 O
0 251 252 653 654 O
) 252 253 654 655 O
, 253 254 655 656 O
unless 255 261 657 663 O
otherwise 262 271 664 673 O
specified 272 281 674 683 O

Antibiotics 0 11 684 695 B-treatment
being 12 17 696 701 O
used 18 22 702 706 O
as 23 25 707 709 O
a 26 27 710 711 O
primary 28 35 712 719 O
treatment 36 45 720 729 B-treatment
of 46 48 730 732 O
Crohn 49 54 733 738 B-chronic_disease
's 54 56 738 740 I-chronic_disease
disease 57 64 741 748 I-chronic_disease

Conventional 0 12 749 761 B-treatment
immunomodulators 13 29 762 778 I-treatment
( 30 31 779 780 O
that 31 35 780 784 O
is 36 38 785 787 O
, 38 39 787 788 O
azathioprine 40 52 789 801 B-treatment
( 53 54 802 803 I-treatment
AZA 54 57 803 806 I-treatment
) 57 58 806 807 I-treatment
, 58 59 807 808 O
6 60 61 809 810 B-treatment
- 61 62 810 811 I-treatment
mercaptopurine 62 76 811 825 I-treatment
( 77 78 826 827 I-treatment
6 78 79 827 828 I-treatment
- 79 80 828 829 I-treatment
MP 80 82 829 831 I-treatment
) 82 83 831 832 I-treatment
, 83 84 832 833 O
or 85 87 834 836 O
Methotrexate 88 100 837 849 B-treatment
( 101 102 850 851 I-treatment
MTX 102 105 851 854 I-treatment
) 105 106 854 855 I-treatment
): 106 108 855 857 O
participants 109 121 858 870 O
must 122 126 871 875 O
have 127 131 876 880 O
been 132 136 881 885 O
taking 137 143 886 892 O
them 144 148 893 897 O
for 149 152 898 901 O
at 153 155 902 904 O
least 156 161 905 910 O
12 162 164 911 913 B-lower_bound
weeks 165 170 914 919 I-lower_bound
and 171 174 920 923 O
at 175 177 924 926 O
a 178 179 927 928 O
stable 180 186 929 935 O
dose 187 191 936 940 O
for 192 195 941 944 O
at 196 198 945 947 O
least 199 204 948 953 O
4 205 206 954 955 B-lower_bound
weeks 207 212 956 961 I-lower_bound
before 213 219 962 968 O
baseline 220 228 969 977 O

Has 0 3 978 981 O
previously 4 14 982 992 O
received 15 23 993 1001 O
a 24 25 1002 1003 O
biologic 26 34 1004 1012 B-treatment
agent 35 40 1013 1018 I-treatment
targeting 41 50 1019 1028 I-treatment
interleukin 51 62 1029 1040 I-treatment
( 63 64 1041 1042 I-treatment
IL)-12 64 70 1042 1048 I-treatment
or 71 73 1049 1051 I-treatment
IL-23 74 79 1052 1057 I-treatment
, 79 80 1057 1058 O
including 81 90 1059 1068 O
but 91 94 1069 1072 O
not 95 98 1073 1076 O
limited 99 106 1077 1084 O
to 107 109 1085 1087 O
ustekinumab 110 121 1088 1099 B-treatment
or 122 124 1100 1102 O
briakinumab 125 136 1103 1114 B-treatment
( 137 138 1115 1116 I-treatment
ABT-874 138 145 1116 1123 I-treatment
) 145 146 1123 1124 I-treatment

Have 0 4 1125 1129 O
Crohn 5 10 1130 1135 B-chronic_disease
's 10 12 1135 1137 I-chronic_disease
disease 13 20 1138 1145 I-chronic_disease
or 21 23 1146 1148 O
fistulizing 24 35 1149 1160 B-chronic_disease
Crohn 36 41 1161 1166 I-chronic_disease
's 41 43 1166 1168 I-chronic_disease
disease 44 51 1169 1176 I-chronic_disease
of 52 54 1177 1179 O
at 55 57 1180 1182 O
least 58 63 1183 1188 O
3 64 65 1189 1190 B-lower_bound
months 66 72 1191 1197 I-lower_bound
' 72 73 1197 1198 O
duration 74 82 1199 1207 O
, 82 83 1207 1208 O
with 84 88 1209 1213 O
colitis 89 96 1214 1221 B-chronic_disease
, 96 97 1221 1222 O
ileitis 98 105 1223 1230 B-chronic_disease
, 105 106 1230 1231 O
or 107 109 1232 1234 O
ileocolitis 110 121 1235 1246 B-chronic_disease
, 121 122 1246 1247 O
confirmed 123 132 1248 1257 O
at 133 135 1258 1260 O
any 136 139 1261 1264 O
time 140 144 1265 1269 O
in 145 147 1270 1272 O
the 148 151 1273 1276 O
past 152 156 1277 1281 O
by 157 159 1282 1284 O
radiography 160 171 1285 1296 B-treatment
, 171 172 1296 1297 O
histology 173 182 1298 1307 O
, 182 183 1307 1308 O
and/or 184 190 1309 1315 O
endoscopy 191 200 1316 1325 B-treatment

Have 0 4 1326 1330 O
active 5 11 1331 1337 O
Crohn 12 17 1338 1343 B-chronic_disease
's 17 19 1343 1345 I-chronic_disease
disease 20 27 1346 1353 I-chronic_disease
, 27 28 1353 1354 O
defined 29 36 1355 1362 O
as 37 39 1363 1365 O
a 40 41 1366 1367 O
baseline 42 50 1368 1376 O
Crohn 51 56 1377 1382 B-clinical_variable
's 56 58 1382 1384 I-clinical_variable
Disease 59 66 1385 1392 I-clinical_variable
Activity 67 75 1393 1401 I-clinical_variable
Index 76 81 1402 1407 I-clinical_variable
( 82 83 1408 1409 I-clinical_variable
CDAI 83 87 1409 1413 I-clinical_variable
) 87 88 1413 1414 I-clinical_variable
score 89 94 1415 1420 I-clinical_variable
of 95 97 1421 1423 O
> 98 99 1424 1425 O
= 99 100 1425 1426 O
220 101 104 1427 1430 B-lower_bound
but 105 108 1431 1434 O
< 109 110 1435 1436 O
= 110 111 1436 1437 O
450 112 115 1438 1441 B-upper_bound

Oral 0 4 1442 1446 B-treatment
5 5 6 1447 1448 I-treatment
- 6 7 1448 1449 I-treatment
aminosalicylic 7 21 1449 1463 I-treatment
acid 22 26 1464 1468 I-treatment
( 27 28 1469 1470 I-treatment
5 28 29 1470 1471 I-treatment
- 29 30 1471 1472 I-treatment
ASA 30 33 1472 1475 I-treatment
) 33 34 1475 1476 I-treatment
compounds 35 44 1477 1486 O

Oral 0 4 1487 1491 B-treatment
corticosteroids 5 20 1492 1507 I-treatment
at 21 23 1508 1510 O
a 24 25 1511 1512 O
prednisone 26 36 1513 1523 B-clinical_variable
- 36 37 1523 1524 I-clinical_variable
equivalent 37 47 1524 1534 I-clinical_variable
dose 48 52 1535 1539 I-clinical_variable
at 53 55 1540 1542 O
or 56 58 1543 1545 O
below 59 64 1546 1551 O
40 65 67 1552 1554 B-upper_bound
milligram 68 77 1555 1564 I-upper_bound
per 78 81 1565 1568 I-upper_bound
day 82 85 1569 1572 I-upper_bound
( 86 87 1573 1574 I-upper_bound
mg 87 89 1574 1576 I-upper_bound
/ 89 90 1576 1577 I-upper_bound
day 90 93 1577 1580 I-upper_bound
) 93 94 1580 1581 I-upper_bound
, 94 95 1581 1582 O
or 96 98 1583 1585 O
9 99 100 1586 1587 O
mg 101 103 1588 1590 O
/ 103 104 1590 1591 O
day 104 107 1591 1594 O
of 108 110 1595 1597 O
budesonide 111 121 1598 1608 B-treatment
, 121 122 1608 1609 O
or 123 125 1610 1612 O
5 126 127 1613 1614 O
mg 128 130 1615 1617 O
/ 130 131 1617 1618 O
day 131 134 1618 1621 O
beclomethasone 135 149 1622 1636 B-treatment
dipropionate 150 162 1637 1649 I-treatment

Woman 0 5 1650 1655 B-gender
who 6 9 1656 1659 O
is 10 12 1660 1662 O
pregnant 13 21 1663 1671 B-pregnancy
or 22 24 1672 1674 I-pregnancy
planning 25 33 1675 1683 I-pregnancy
pregnancy 34 43 1684 1693 I-pregnancy
or 44 46 1694 1696 O
is 47 49 1697 1699 O
a 50 51 1700 1701 O
man 52 55 1702 1705 O
who 56 59 1706 1709 O
plans 60 65 1710 1715 O
to 66 68 1716 1718 O
father 69 75 1719 1725 O
while 76 81 1726 1731 O
randomized 82 92 1732 1742 O
in 93 95 1743 1745 O
the 96 99 1746 1749 O
study 100 105 1750 1755 O
or 106 108 1756 1758 O
within 109 115 1759 1765 O
16 116 118 1766 1768 B-upper_bound
weeks 119 124 1769 1774 I-upper_bound
after 125 130 1775 1780 O
the 131 134 1781 1784 O
last 135 139 1785 1789 O
administration 140 154 1790 1804 O
of 155 157 1805 1807 O
study 158 163 1808 1813 O
agent 164 169 1814 1819 O

